Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
Globe Newswire•30/09/2026•07:30 ET
2
Key Highlights
- ➤Q3 CNSide billings $1.55 million from 222 tests, unaudited
- ➤TCE Test contracted coverage reaches 158 million lives, targeting 200 million by early 2027
- ➤CMS preliminarily favors CNSide PLA code 0640U pricing, effective January 1, 2027
- ➤CNSide targets $10 million-$12 million annualized gross billing rate in Q4 2026
- ➤Expanded CSF and breast cancer testing menu launches planned for Q4 2026
Expert Statements
Russell Bradley, President and General Manager of CNSide Diagnostics
“Over the past few months, we have built the foundation of a reimbursed diagnostics business including clinical evidence, payer contracts, a dedicated billing code, positive CMS Medicare coverage progress, laboratory accreditation and billing infrastructure.”
Russell Bradley, President and General Manager of CNSide Diagnostics
“We are on track to continue that progress across multiple areas of the business for the remainder of the year, and our team is excited about the future of CNSide.”
Lead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meeting
On track to launch expanded CNSide testing menu with multiple tests in Q4 2026
Get started
Create a free account to read the full story.